The marker is a urinary metabolite, the polyamine DiAcSpm, not microRNA. Published in the Journal of Gastrointestinal Cancer Screening; 78 healthy adults and 125 cancer patients; the authors call the work a preliminary evaluation.
TOKYO, March 13, 2025 - Craif Inc., a bio-AI company developing a urine analysis platform for early detection of cancer and other diseases, which provides the urine-based cancer risk test miSignal, said research evaluating the usefulness of a urinary metabolite for early screening of gastrointestinal cancer has been published. The metabolite is N1, N12-diacetylspermine, abbreviated DiAcSpm. The cancers studied were pancreatic, gastric and colorectal. The paper appears in the March 2025 issue of the Journal of Gastrointestinal Cancer Screening.
This study measures a urinary metabolite, not microRNA. DiAcSpm is a polyamine that cancer cells excrete into urine as they proliferate, and the authors measured it here by ELISA immunoassay.
What the study found
- Creatinine corrected urinary DiAcSpm (DiAcSpm/Cre) was significantly higher in cancer patients than in healthy adults (p < 0.001).
- Area under the ROC curve reached 0.88 at Stage I for colorectal cancer and at Stage I for gastric cancer. Craif describes this as promising diagnostic performance for screening.
- In pancreatic cancer, urinary DiAcSpm rose as the cancer advanced, and diagnostic performance improved with stage. The authors note this pattern resembles that of CA19-9, an established tumor marker.
- The authors describe this as the first report of urinary DiAcSpm performance specifically for gastric cancer detection.
What the study did
The authors analyzed urine samples from 78 healthy adults and 125 cancer patients, measured urinary DiAcSpm concentration by ELISA, and assessed diagnostic performance using ROC curve analysis.
The authors describe the work as a preliminary evaluation. It is a case-control comparison of samples from patients already known to have cancer against samples from healthy adults. It is not a screening trial in a general population, and no operating cutoff is reported.
Why a urine-based step matters in Japan
Endoscopy uptake in Japan is low, and the number of institutions and physicians able to perform endoscopy is limited. Raising participation alone does not solve that. Craif believes what is also needed is risk stratification that identifies in advance the people who should be scoped.
Because the test needs only a urine sample, Craif positions it as a way to identify a higher-risk group to refer for endoscopy. Directing that group toward endoscopy could raise early detection rates and put scarce endoscopy capacity where it is most likely to find disease. DiAcSpm has been studied for some time as a urinary biomarker with potential across several early-stage cancers, and its main practical advantage is that it is non-invasive.
What comes next
Risk assessment using urinary DiAcSpm is already in commercial use in Japan as miSignal Lite. Craif says it will collect more data from Japanese cancer patients to establish a cancer screening test based on urinary DiAcSpm, and that combining the marker with existing screening methods should support efficient risk stratification and earlier diagnosis.
The paper also raises, as a possibility for future work rather than as a result, that combining DiAcSpm with biomarkers reported to be strong at detecting early-stage pancreatic cancer, including urinary microRNA, may raise detection performance further. That combination was not tested in this study.
The miSignal series is not a medical device. It determines risk by statistically calculating analyzed information. It is not a substitute for a medical diagnosis of whether a person has cancer, and a low-risk result does not mean that cancer is absent or that a person will not develop cancer in the future.
Publication details
Journal: Journal of Gastrointestinal Cancer Screening (日本消化器がん検診学会雑誌), March 2025 issue. Published in Japanese.
Title (English translation): Preliminary Evaluation of the Utility of Urinary N1,N12-Diacetylspermine in Early Screening of Gastrointestinal Cancers.
Authors: Kazuya Takayama, Mika Mizunuma, Masanori Hirano, Motoki Mikami, Yuichi Sugimura, Hiroki Ichikawa.
DOI: https://doi.org/10.11404/jsgcs.63.83
Glossary
- N1, N12-diacetylspermine (DiAcSpm): a polyamine excreted into urine when cancer cells are actively proliferating. Urinary concentration is known to rise as cancer progresses.
- ROC analysis (receiver operating characteristic analysis): a statistical method for evaluating diagnostic test performance. It plots the relationship between sensitivity and specificity, and expresses accuracy as a single number, the area under the curve.
- AUC (area under the curve): an index from ROC analysis on a scale of 0 to 1. Values closer to 1 indicate higher diagnostic accuracy, and 0.80 or above is generally considered high diagnostic performance.
- Sensitivity and specificity: sensitivity is the proportion of people with the disease who test positive, calculated as true positives divided by true positives plus false negatives. Specificity is the proportion of people without the disease who test negative, calculated as true negatives divided by true negatives plus false positives.
- Creatinine correction: standardizing a urinary biomarker concentration against urinary creatinine concentration to correct for urine dilution, making results more reliable.
About Craif
Craif is a bio-AI company founded in 2018 that develops non-invasive tests for the early detection of cancer. Its platform combines proprietary biomarker detection from urine and other bodily fluids with AI to assess disease risk. Building on one of the world's largest urine datasets, Craif aims to create a urine analysis platform that detects a wide range of diseases early, with cancer as the first step. The company is based in Tokyo and operates a wholly owned laboratory in San Diego, opened in 2026. Learn more at craif.com.
